Galena Biopharma Announces Purchase Agreement for Up to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Galena Biopharma Announces Purchase Agreement for Up to $55.0 Million With Lincoln Park Capital Fund, LLC
  • Initial Purchase of $5.0 Million at $2.00 per share, 9% higher than the market close as of November 18, 2014
  • Agreement structure provides Galena control and flexibility to access capital over the long-term to fund the Company's clinical and development programs

PORTLAND, Ore., Nov. 20, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. ("Galena" or the "Company") (Nasdaq: GALE ), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care announced today the execution of a purchase agreement for up to $55.0 million with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor.

Under the terms of the purchase agreement dated November 18, 2014, LPC initially purchased $5.0 million dollars of Galena common stock at a price of $2.00 per share, 9% higher than the market close as of November 18, 2014. Thereafter, at its sole discretion, Galena may sell up to $50 million worth of common stock to LPC over the 36-month term of the purchase agreement, subject to the conditions and limitations set forth in the purchase agreement. Under the terms of the purchase agreement, LPC will not cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of Galena common stock and is obligated to purchase at times and amounts controlled by the Company. In consideration for entering into the agreement the Company issued shares of its common stock to LPC as a commitment fee.

Galena plans to use the proceeds received for its commercial and product development activities and for other working capital and general corporate purposes.

Mark W. Schwartz, Ph.D., President and Chief Executive Officer of Galena Biopharma, stated, "This funding mechanism from Lincoln Park Capital, an established healthcare investment firm, provides Galena with strategic, long-term access to capital in order to execute on our clinical and commercial programs as we approach multiple milestones over the next several quarters. Importantly, this structure allows us complete control and flexibility to access capital at the appropriate times, coinciding with the progress of the Company."

Additional information regarding this financing is available in the Current Report on Form 8-K that the Company filed today with the Securities and Exchange Commission ("SEC"). The securities described above are being offered pursuant to a shelf registration statement (File No. 333-188847) that was declared effective by the SEC on June 12, 2013. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The offering can be made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained at the SEC's website at www.sec.gov or by request from the Company at 4640 SW Macadam Avenue, Suite 270, Portland, Oregon 97239 or by telephone at (503) 400-6610.

About Galena Biopharma

Galena Biopharma, Inc. (Nasdaq: GALE ) is a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care. Galena's development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax™ (nelipepimut-S) currently in an international, Phase 3 clinical trial. The Company's commercial drugs include Abstral ® (fentanyl) Sublingual Tablets and Zuplenz ® (ondansetron) Oral Soluble Film. Collectively, Galena's clinical and commercial strategy focuses on identifying and advancing therapeutic opportunities to improve cancer care, from direct treatment of the disease to the reduction of its debilitating side-effects. For more information, visit www.galenabiopharma.com .

About Lincoln Park Capital Fund, LLC (LPC)

LPC is an institutional investor headquartered in Chicago, Illinois. LPC's experienced professionals manage a portfolio of investments in public and private entities. These investments are in a wide range of companies and industries emphasizing life sciences, specialty finance, energy and technology. LPC's investments range from multiyear financial commitments to fund growth to special situation financings to long-term strategic capital offering companies flexibility and consistency. For more information, visit www.lpcfunds.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those identified under "Risk Factors" in Galena's Annual Report on Form 10-K for the year ended December 31, 2013 and most recent Quarterly Reports on Form 10-Q filed with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Galena does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release.

Remy Bernarda Vice President, Marketing & Communications (503) 405-8258

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Gives CPA Firms a New Advisory Staffing Math Today

Updated Category News Views 75

Month-end just got a lot less comfortable for firms living on the clock. Netsurit and Southwestern Talent are pitching the Virtual CFO Platform as a way for CPA firms to turn machine-led analysis into advisory work without first building a costly bench of specialists. That is not a cute workflow tweak. It goes straight at the labor model that has kept plenty of accounting...

Continue Reading
Premier Energy's €850M Debt Bet on Evryo Nears Close

Updated Category News Views 117

A Bridge Loan Gives Way to a Real Commitment Eight hundred and fifty million euros is not the sort of number a company tosses around for decoration. Premier Energy has secured a five-year senior facilities agreement to fund its planned acquisition of Evryo Group, including electricity distribution subsidiary Distribu?ie Energie Oltenia S.A., and to refinance roughly...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 118

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 174

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Telit Cinterion Tests Its Defense Connectivity Pitch

Updated Category News Views 107

Defense connectivity is a messy business, and Telit Cinterion is leaning straight into the mess at NATO Edge 2026 in Izmir, Turkey. From November 17 through 19, the company is using Booth L86 to show how several wireless links can live inside one mission-focused setup. That may sound like standard trade-show wallpaper, but the underlying problem is very real: military and...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 194

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading
Ivanti's AI Push Rests on Data, Control and Results

Updated Category News Views 216

Enterprise AI has a nasty habit of sounding brilliant right up until it meets a messy fleet of laptops, phones, patches and permissions. Ivanti’s latest product push is aimed squarely at that unglamorous collision point: giving AI systems governed access to the operational data inside Ivanti Neurons, then keeping humans and pre-set permissions in charge of what happens...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 122

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 158

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 148

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading

Top 5 Most Recently Viewed Articles

Survey Reveals Enterprises Unready for Rising AI Power Needs

Updated Category News Views 257

Understanding the Readiness Gap in AI Power Demand Recent research sheds light on a concerning trend among enterprises regarding their preparedness to meet the escalating power demands posed by artificial intelligence (AI). Conducted by SambaNova, this survey demonstrates that while many leaders acknowledge the urgent need for energy management in AI, only a fraction...

Continue Reading
Ellevio Reports Solid Gains in H1 Despite Cash Flow Dip

Updated Category News Views 47

In a world where the electricity flows must keep pace with surging demands and regulatory labyrinths, Ellevio AB is not just hanging in there; it's pushing forward with gusto. They've just released their Half-year Report for 2026, and the numbers show a steady pulse amidst the evolving Swedish energy market conditions. With key stakeholders like OMERS Infrastructure and...

Continue Reading
Dan Orlando Releases Captivating New Music Video for Fans

Updated Category News Views 219

Dan Orlando's Artistic Journey Shines in New Video Musician Dan Orlando has just released his newest music video, 'Music In My Head.' This marks an important step in his artistic journey, showcasing his growth and dedication to producing music that resonates across various styles. A Heartfelt Connection with His Audience The video for 'Music In My Head' highlights...

Continue Reading
Revolutionizing API Testing with Parasoft's Agentic AI

Updated Category News Views 513

Parasoft Enhances API Testing with Agentic AI Parasoft, a global leader in AI-driven software testing solutions, has unveiled its latest innovation: the Agentic AI approach. This groundbreaking feature aims to transform API testing, making it more efficient and effective for software development teams. By integrating intelligent, outcome-based scenario testing, Parasoft...

Continue Reading
PPL Corporation's Growth Continues: Q1 Insights Unpacked

Updated Category News Views 193

PPL Corporation Reports Impressive First Quarter Earnings PPL Corporation (NYSE: PPL) has posted remarkable financial results for the first quarter, demonstrating solid performance and strategic execution. The company's reported earnings per share (EPS) for the quarter stands at $0.56, a significant increase compared to $0.42 in the previous year. Notably, ongoing...

Continue Reading